Influence of the Lycopid and Immunal Immunomodulators on the Helicobacter Pylori Eradication at a Treatment of the Stomach Duodenum Ulcerous Disease
Aim of investigation is revealing of the Helicobacter pylori eradication effectiveness increase possibility in patients with the stomach and duodenum ulcerous disease, associated with H. pylori, by the licopid, immunal and «quadro-scheme» immunomodulator combined use and detection of the immunity humoral and cellular link values.
Materials and Methods. 70 patients at the age of 20—55 years with the stomach and duodenum ulcerous disease, associated with H. pylori, were included into investigation. The samples of bioptates, blood biotests were the objects of investigation.
Results. It is established, that the immunomodulaator use in combination with the antichelicobacter therapy leads to the eradication degree and immunity tension increase. Besides, a licopid use has demonstrated the cellular and humoral immunity increase, and the immunal use — a cellular immunity mainly.
